



Endologix
Investor Relations Department
2 Musick
Irvine, CA 92618
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ELGX

Last Trade:	4.98
Trade Time:	4:00 PM ET Jun 28, 2017
Change:	-0.12 ↓ (-2.353%)
Day Range	4.95 - 5.12
52-Week Range	4.21 - 14.50
Volume	671,666

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

Stock Performance



Press Releases [\[View all \]](#)

Jun 3, 2017

[Endologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial](#)

May 31, 2017

[Endologix Reports Positive Clinical Data from the Ovation LUCY Study](#)

May 17, 2017

[Endologix Provides an Update on the Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory Status](#)

May 4, 2017

[Endologix Reports First Quarter 2017 Financial Results](#)

Apr 24, 2017

[Endologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm Sealing System Presentation at the Society of Vascular Surgery Annual Meeting on June 3, 2017](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)